Detalles de la búsqueda
1.
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Lancet Gastroenterol Hepatol;
8(1): 43-55, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36240801
2.
Dual targeting of lymphocyte homing and retention through α4ß7 and αEß7 inhibition in inflammatory bowel disease.
Cell Rep Med;
2(8): 100381, 2021 08 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34467254
Resultados
1 -
2
de 2
1
Próxima >
>>